Findings showed a 13.6% reduction in body weight in the semaglutide 25 mg group compared with a 2.2% reduction in the placebo group.

Oral semaglutide was initiated with a 4-week dose ... 146 mg/dL. Most were on glucose-lowering therapies like metformin (87%) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) (37.5%).

4,5 The expanded analysis of ESSENCE showed ... By Week 72, 88% of participants received and maintained the full target dose of semaglutide 2.4 mg. No new safety signals emerged, and the safety ...